Sentence examples for patients bid from inspiring English sources

AVERROES was a superiority trial in patients (n= 5599) who had failed or were unsuitable for VKA prophylaxis, comparing apixaban 5 mg (or 2.5 mg in selected patients) bid with ASA (81 324 mg per day).As with ARISTOTLE, the primary efficacy endpoint was the occurrence of stroke (ischaemic or haemorrhagic) or systemic embolism.

Common procedures could be exposed to open market forces that set prices and allow patients to bid around those prices to achieve maximum value.

In metformin-treated patients, exenatide BID was noninferior to PIA for glycemic control but superior for hypoglycemia and weight control.

In metformin-treated type 2 diabetic patients, exenatide BID was noninferior to PIA in terms of glycemic control and superior in terms of hypoglycemia.

Overall discontinuation rates were low and similar between groups: 6% of ticagrelor 90 mg bid patients; 7% of patients receiving 180 mg bid; and 6% of patients receiving clopidogrel 75 mg qd.

Conclusion: In patients requiring FP250 bid for asthma stability, FP100/salmeterol bid was steroid-sparing, allowing a 60% reduction in the FP dose while maintaining overall asthma control.

Greater reductions in plasma HIV-1 RNA levels were also observed in patients receiving APV600/RTV BID than those using APV1200 BID.

Hypotension was also more common in ticagrelor groups, occurring in 1.2% of ticagrelor 90 mg bid patients: 3.7% of ticagrelor 180 mg bid patients and 0.6% of clopidogrel 75 mg qd patients.

Responses in the "mildly", "moderately" or "severely" disordered states were given by 16.3%, 10.0% and 2.7% of exenatide BID patients and 17.9%, 11.8% and 3.7% of insulin patients.

After 26 weeks, exenatide BID patients had lost 4.1 ± 0.22 kg of weight, while PIA patients had gained 1.0 ± 0.22 kg (LS mean ± SEM; P < 0.001 for group difference).

Responses in the "mildly", "moderately" or "severely" disordered states were given by 18.2%, 13.2% and 4.2% of exenatide BID patients and 20.8%, 14.6%, and 5.7% of insulin patients, respectively.